Volitionrx News

3,0501 $ -2,85% -0,0895 $
In Euro: 2,4743 € | 19:52 Uhr AMEX | Mehr Kurse »
WKN: A12B6K
ISIN: US9286611077
US-Symbol: VNRX
Typ: Aktie

Volitionrx News

13.08.14 VolitionRx Invests in Laboratory Automation System to Increase Throughput Capacity for Large Clinical Trials PR Newswire
01.07.14 VolitionRx Announces New Chief Financial Officer PR Newswire
23.06.14 VolitionRx Sells First NuQ® Research Use Only Kits to Active Motif PR Newswire
02.12.13 VolitionRx Finds Simple Blood Test Detects 85% of Colorectal Cancers and Over 50% of Polyps PR Newswire
29.11.13 VolitionRx to Present at the 6th Annual LD Micro Conference PR Newswire
14.11.13 VolitionRx Expands Sample Size to 11,000 in Pivotal Colorectal Cancer Trial with Hvidovre Hospital, Denmark PR Newswire
14.11.13 VolitionRx Expands Sample Size to 11,000 in Pivotal Colorectal Cancer Trial with Hvidovre Hospital, Denmark PR Newswire
07.11.13 First VolitionRx Study Data Presented at CNAPS, Baltimore PR Newswire
26.09.13 VolitionRx and Active Motif enter into Distribution Agreement for Volition's Research Use Only ELISA Kits PR Newswire
03.09.13 VolitionRx-​led Consortium Awarded euro 780 000 ($1M approx.) Eurostars Grant PR Newswire
22.07.13 VolitionRx to use Innova Biosciences' Biotin Technology in its Epigenetic Research Kits PR Newswire
29.05.13 VolitionRx Embarks on Colorectal Cancer Trial with Hvidovre Hospital, Denmark PR Newswire
01.05.13 Racepoint Group Appointed by VolitionRx to Raise Awareness of its new Early-​Stage Cancer Diagnostic PR Newswire
04.04.13 VolitionRx Files Two Patent Applications PR Newswire
26.03.13 VolitionRx Hires Head of US Operations, Jason Terrell MD PR Newswire
09.01.13 VolitionRx Announces Collaboration with Wales Cancer Bank PR Newswire
17.12.12 Volition Launches NuQ® Epigenetic Immunoassays for Research Use PR Newswire
05.11.12 VolitionRx's Preliminary Diagnostic Clinical Trial Results Show High Sensitivity and Specificity for Colon, Breast and Lung Cancers PR Newswire
21.08.12 VolitionRX to Begin Prospective Clinical Trial in Colon Cancer PR Newswire
16.07.12 VolitionRX Issues CEO Letter to Shareholders PR Newswire
09.07.12 VolitionRX Signs Collaboration Agreement With Stefan Holdenrieder of Rheinische Friedrich-​Wilhelms-Universitat Bonn Germany PR Newswire

Newssuche